The current state of therapeutic and T cell-based vaccines against human papillomaviruses

Yang, Andrew; Farmer, Emily; Lin, John; Wu, T. C.; Hung, Chien Fu

doi:10.1016/j.virusres.2016.12.002

Cited by 54 publications

(46 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VitD therapy has been attempted for certain autoimmune diseases [44][45][46], based on results in animal models showing that VitD can PLOS ONE increase the ratio of Treg to Th17 cells [47,48]. During the past decade there have been numerous clinical trials to restore immune health in people exposed to HIV [49,50] and other infectious diseases [51] using VitD supplementation.…”

Section: Discussionmentioning

confidence: 99%

Arsenic exposure associated T cell proliferation, smoking, and vitamin D in Bangladeshi men and women

et al. 2020

View full text Add to dashboard Cite

There are limited data examining the consequences of environmental exposure to arsenic on the immune system in adults, particularly among smokers. Smoking has been shown to exacerbate or contribute to impaired immune function in men chronically exposed to arsenic. In contrast, vitamin D (VitD) is known to have a positive influence on innate and adaptive immune responses. The effect of circulating VitD on arsenic-associated immune dysfunction is not known. Here we examine the relationship of arsenic exposure and T cell proliferation (TCP), a measure of immune responsiveness, and circulating VitD among adult men and women in Bangladesh. Arsenic exposure was assessed using total urinary arsenic as well as urinary arsenic metabolites all adjusted for urinary creatinine. TCP was measured ex vivo in cryopreserved peripheral blood mononuclear cells from 614 adult participants enrolled in the Bangladesh Health Effects of Arsenic Longitudinal Study; serum VitD was also evaluated. The influence of cigarette smoking on arsenic-induced TCP modulation was assessed only in males as there was an inadequate number of female smokers. These studies show that arsenic suppressed TCP in males. The association was significantly strong in male smokers and to a lesser extent in male non-smokers. Interestingly, we found a strong protective effect of high/sufficient serum VitD levels on TCP among non-smoking males. Furthermore, among male smokers with low serum VitD (t20 ng/ml), we found a strong suppression of TCP by arsenic. On the other hand, high VitD (>20 ng/ml) was found to attenuate effects of arsenic on TCP among male-smokers. Overall, we found a strong protective effect of VitD, when serum levels were >20 ng/ml, on arsenic-induced inhibition of TCP in men,

show abstract

Section: Discussionmentioning

confidence: 99%

Arsenic exposure associated T cell proliferation, smoking, and vitamin D in Bangladeshi men and women

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The prophylactic vaccines are relatively safer ( 56 – 58 ). It is interesting to note that there is enhancement of cell mediated immunity by T cell based vaccines in contrast to prophylactic vaccines (that help in generating neutralizing antibodies) ( 59 ). At present, the questions that arise regarding vaccination against HPV is the protection period (specially, in relation to cross protection).…”

Section: Hpv Diseasementioning

confidence: 99%

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

Dadar

Chakraborty²,

Dhama

et al. 2018

Front. Immunol.

View full text Add to dashboard Cite

Human papillomavirus (HPV) is a viral infection with skin-to-skin based transmission mode. HPV annually caused over 500,000 cancer cases including cervical, anogenital and oropharyngeal cancer among others. HPV vaccination has become a public-health concern, worldwide, to prevent the cases of HPV infections including precancerous lesions, cervical cancers, and genital warts especially in adolescent female and male population by launching national programs with international alliances. Currently, available prophylactic and therapeutic vaccines are expensive to be used in developing countries for vaccination programs. The recent progress in immunotherapy, biotechnology, recombinant DNA technology and molecular biology along with alternative and complementary medicinal systems have paved novel ways and valuable opportunities to design and develop effective prophylactic and therapeutic vaccines, drugs and treatment approach to counter HPV effectively. Exploration and more researches on such advances could result in the gradual reduction in the incidences of HPV cases across the world. The present review presents a current global scenario and futuristic prospects of the advanced prophylactic and therapeutic approaches against HPV along with recent patents coverage of the progress and advances in drugs, vaccines and therapeutic regimens to effectively combat HPV infections and its cancerous conditions.

show abstract

“…So far, many different vectors and main targets have been developed, but most of these therapeutic vaccines have failed at the clinical stage even though the results in experimental models have been promising [80]. In addition, the majority of therapeutic vaccines have not been shown to be efficient enough to destroy the already developed cancerous tissue [79, 81, 82]. Plausibly, after finding the right HLA allele targets that could also be used among gene pools of different populations, the HPV-specific HLA markers could have the potential of becoming reliable and cost-effective preventive HPV biomarkers for early cancer detection.…”

Section: Discussionmentioning

confidence: 99%

From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity

et al. 2019

View full text Add to dashboard Cite

Persistent high-risk human papillomavirus (HPV) infection has been associated with increased risk for cervical precancerous lesions and cancer. The host’s genetic variability is known to play a role in the development of cervical cancer. The human leukocyte antigen (HLA) genes are highly polymorphic and have shown to be important risk determinants of HPV infection persistence and disease progression. HLA class I and II cell surface molecules regulate the host’s immune system by presenting HPV-derived peptides to T-cells. The activation of T-cell response may vary depending on the HLA allele polymorphism. The engagement of the T-cell receptor with the HPV peptide-HLA complex to create an active costimulatory signal is essential for the activation of the T-cell response. Functional peptide presentation by both HLA class I and II molecules is needed to activate efficient helper and effector T-cell responses in HPV infection recognition and clearance. Some of these HLA risk alleles could also be used as preventive tools in the detection of HPV-induced cervical lesions and cancer. These HLA alleles, together with HPV vaccines, could potentially offer possible solutions for reducing HPV-induced cervical cancer as well as other HPV-related cancers.

show abstract

The current state of therapeutic and T cell-based vaccines against human papillomaviruses

Cited by 54 publications

References 92 publications

Arsenic exposure associated T cell proliferation, smoking, and vitamin D in Bangladeshi men and women

Arsenic exposure associated T cell proliferation, smoking, and vitamin D in Bangladeshi men and women

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity

Contact Info

Product

Resources

About